This webcast was recorded at a live event at ASCO SITC 2018. During this event, three leading experts challenged participants with quiz questions, which formed a basis for in-depth discussions supported by slide presentations. Participants were able to test and expand their knowledge on the increasingly important role of biomarkers in immuno-oncology. The experts examined the tumor microenvironment and addressed the evidence base for, and the future potential of, current and emerging biomarkers in guiding treatment decisions and in predicting the response to immuno-oncology therapeutics. Participants also learned about the role and importance of next-generation sequencing for the evaluation of novel immune biomarkers and for daily clinical practice.
Elsevier's complimentary continuing medical education courses in pathology are targeted to healthcare providers in lab medicine.
This webcast on relapsed/refractory acute lymphoblastic leukemia (R/R ALL) is based on a roundtable discussion by three experts, who provide an overview of challenges in the treatment of R/R ALL and summarize and discuss the latest data presented during the European Hematology Association (EHA) Annual Congress 2017, held on June 22–25 in Madrid, Spain. Progressing clinical trial outcomes of targeted therapies for R/R ALL, such as the anti-CD22 immunoconjugate inotuzumab ozogamicin, the anti-CD19 bi-specific T-cell engager (BiTE) blinatumomab, and CAR-T cell therapy will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with R/R ALL.
This webcast on metastatic renal cell carcinoma (mRCC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of mRCC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, on September 8–12, 2017. Advances in the use of targeted therapies such as VEGFR inhibitors, novel immunotherapies, and combination therapies including PD-1/PD-L1 and CTLA4 targeting agents will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with mRCC.
ESMO 2017: A Therapeutic Update on the Management of Patients with Advanced Hepatocellular CarcinomaFormat: Medical Meeting Reporter
This webcast on hepatocellular carcinoma (HCC) is based on a presentation by an expert, who provides an overview of the advances in the management of HCC and summarizes and discusses the latest data presented during the European Society for Medical Oncology (ESMO) Annual Meeting 2017, held on September 8-12 in Madrid, Spain. Results of clinical trials of targeted therapies that have been evaluated in first-line and second-line setting in advanced HCC and their possible effect on treatment guidelines will be examined. Additionally, the potential role of biomarkers as prognostic factors of response to targeted therapies, particularly in clinical practice, will also be discussed. The expert will also discuss the most promising new agents in advanced clinical trials in HCC and how they might impact the treatment landscape in HCC.